Table 3.
A list of potential lncRNAs that can be therapeutic targeted in cancer
| lncRNA | Function | Reported cancer type | Mechanism | REF |
|---|---|---|---|---|
| ANRIL | Oncogene | Bladder, lung, liver, cervical, stomach | Interacts with PRC2 and CBX7 | [207] |
| BANCER | Oncogene | Stomach, skin | Promotes proliferation and metastasis via regulation of NF-kB1, p21, MAPK pathways | [208, 209] |
| CCAT1-L | Oncogene | Colon | Transcriptionally regulates MYC and promotes long-range chromatin looping | [210] |
| CCAT2 | Oncogene | Esophagus, stomach, breast, colon | Enhances Wnt signaling pathway via TCF7L2 interaction | [211–213] |
| CRNDE | Oncogene | Colon | Negatively regulated by insulin and insulin-like growth factors and may regulate the expression of genes involved in metabolism | [214] |
| HCP5 | Oncogene | Stomach | Sequesters miR-3619-5p and upregulates PPARGC1A, which Induces stemness and drug resistance | [215] |
| HOTAIR | Oncogene | Esophagus, stomach, colon, liver, lung, breast, ovary, bladder, prostate, glioma, melanoma | Serves as a scaffold to assemble PRC2 and LSD1 complexes to the HOXD gene cluster. Epigenetic silencing of HOXD genes in multiple tissues | [216] |
| HULC | Oncogene | Liver, pancreas | Modulates abnormal lipid metabolism through miR-9-mediated RXRA signaling pathway | [217, 218] |
| lincRNA-ATB | Oncogene | Liver, breast, colon, pancreas | miR-200 family sponge. Upregulates ZEB1 and ZEB2. | [219] |
| lincRNA-ROR | Oncogene | Breast | Competitive endogenous RNA for miR-145 | [220, 221] |
| MALAT 1 | Oncogene | Lung, prostate colon, liver | Forms molecular scaffolds for ribonucleoprotein complexes in the nucleus. Transcriptional regulator for genes involved in cell cycle regulation, cancer metastasis, and cell migration. | [222–224] |
| MCF2L-AS1 | Oncogene | Colon | Enhances cell proliferation and invasion through crosstalk with miR-874-3p/FOXM1 signaling axis | [133] |
| PCA3 | Oncogene | Prostate | Enhances cell proliferation through regulation of PRUNE2 | [225] |
| PRNCR 1 (PCAT8) | Oncogene | Colon, prostate | Binds to the androgen receptor and enhances ligand-dependent and ligand-independent androgen-receptor-mediated gene activation and increases proliferation | [226, 227] |
| PVT-1 | Oncogene | Breast, bladder, colon, kidney, pancreas | Regulates MYC oncogene | [228] |
| UCA1 | Oncogene | Colon, bladder, breast, esophagus, stomach, liver, skin | Regulates CREB | [229] |
| GAS5 | Tumor suppressor | Breast, prostate, lung | Encodes glucocorticoid response element, which binds to the DNA binding domain and blocks the activity of glucocorticoid receptor, androgen, progesterone, and mineralocorticoid. | [230] |
| H19 | Tumor suppressor | Breast, lung, pancreas, stomach, bladder, prostate, colon, skin | Cancer metastasis tumor suppressor and generates miR-675 | [231] |
| lincRNA-p21 | Tumor suppressor | Colon | Enhances p21 activity | [232] |
| MEG3 | Tumor suppressor | Brain, bladder, bone marrow, breast, colon, liver, lung, prostate | Interacts with the tumor suppressor p53 and regulates its target gene expression. | [233] |
| ncRuPAR | Tumor suppressor | Colon, stomach | Inhibits tumor progression by downregulation of protease-activated receptor-1(PAR-1) | [210] |
| TUG1 | Tumor suppressor | Bladder, esophagus | Regulates miR-145. Suppresses epithelial-to-mesenchymal transition and radio-resistance. | [229, 234] |